{{Drugbox
| IUPAC_name = 2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol
| image = CP 55,940-2D-skeletal.svg
| width = 200px
<!--Clinical data-->
| tradename =  
| legal_status =  
| legal_CA = Schedule II
| routes_of_administration =  
<!--Pharmacokinetic data-->
| metabolism =  
| elimination_half-life =  
| excretion =  
<!--Identifiers-->
| CAS_number = 83002-04-4
| PubChem = 3086156
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 559612
|  ChemSpiderID = 94668

<!--Chemical data-->
| C=24 | H=40 | O=3
| molecular_weight = 376.573 g/mol
|  StdInChI = 1S/C24H40O3/c1-4-5-6-7-14-24(2,3)19-11-13-21(23(27)16-19)22-17-20(26)12-10-18(22)9-8-15-25/h11,13,16,18,20,22,25-27H,4-10,12,14-15,17H2,1-3H3/t18-,20-,22-/m1/s1
|  StdInChIKey = YNZFFALZMRAPHQ-SYYKKAFVSA-N
| smiles = O[C@H]1C[C@@H](C2=CC=C(C(C)(C)CCCCCC)C=C2O)[C@H](CCCO)CC1
}}
'''CP 55,940''' is a [[cannabinoid]] which mimics the effects of naturally occurring [[Tetrahydrocannabinol|THC]] (one of the psychoactive compounds found in [[cannabis]]). CP 55,940 was created by [[Pfizer]] in 1974 but was never marketed. It is currently used to study the [[endocannabinoid system]].

A study found that CP 55,940 can upregulate [[5-HT2A receptor|5-HT<sub>2A</sub>]] receptors in mice.<ref>{{cite journal |author1=Franklin, J. M. |author2=Carrasco, G. A. | title = Cannabinoid receptor agonists upregulate and enhance serotonin 2A (5-HT<sub>2A</sub>) receptor activity via ERK1/2 signaling | journal = Synapse | year = 2013 | volume = 67 | issue = 3 | pages = 145–159 | pmid = 23151877 | doi = 10.1002/syn.21626 | pmc=3552103}}</ref>

CP 55,940 is 45 times more potent than Δ<sup>9</sup>-THC, and fully antagonized by [[rimonabant]] (SR141716A).<ref>{{cite journal |author1=Rinaldi-Carmona, M. |author2=Pialot, F. |author3=Congy, C. |author4=Redon, E. |author5=Barth, F. |author6=Bachy, A. |author7=Brelière, J. C. |author8=Soubrié, P. |author9=le Fur, G. | year = 1996 | title = Characterization and distribution of binding sites for [<sup>3</sup>H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain | journal = Life Sciences | volume = 58 | issue = 15 | pages = 1239–1247 | pmid = 8614277 | doi = 10.1016/0024-3205(96)00085-9 }}</ref>

CP 55,940 is considered a full agonist at both CB<sub>1</sub> and CB<sub>2</sub> receptors and has [[Disassociation constant#Protein-ligand binding|K<sub>i</sub>]] values of 0.58nM and 0.68nM respectively, but is an antagonist at [[GPR55]], the putative "CB<sub>3</sub>" receptor.<ref>{{ cite journal |author1=Kapur, A. |author2=Zhao, P. |author3=Sharir, H. |author4=Bai, Y. |author5=Caron, M. G. |author6=Barak, L. S. |author7=Abood, M. E. | title = Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands | journal = The Journal of Biological Chemistry | year = 2009 | volume = 284 | issue = 43 | pages = 29817–29827 | pmid = 19723626 | doi = 10.1074/jbc.M109.050187 | pmc = 2785612 }}</ref>

CP 55,940 showed protective effects on rat brain mitochondria upon paraquat exposure.<ref>{{ cite journal |author1=Velez-Pardo, C. |author2=Jimenez-Del-Rio, M. |author3=Lores-Arnaiz, S. |author4=Bustamante, J. | title = Protective effects of the synthetic cannabinoids CP55,940 and JWH-015 on rat brain mitochondria upon paraquat exposure | journal = Neurochemical Research | year = 2010 | volume = 35 | issue = 9 | pages = 1323–1332 | pmid = 20514518 | doi = 10.1007/s11064-010-0188-1 }}</ref>

It also showed neuroprotective effects by reducing intracellular calcium release and reducing hippocampal cell death in cultured neurons subjected to high levels of NMDA.<ref>{{ cite journal |author1=Zhuang, S. Y. |author2=Bridges, D. |author3=Grigorenko, E. |author4=McCloud, S. |author5=Boon, A. |author6=Hampson, R. E. |author7=Deadwyler, S. A. | title = Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores | journal = Neuropharmacology | year = 2005 | volume = 48 | issue = 8 | pages = 1086–1096 | pmid = 15910885 | doi = 10.1016/j.neuropharm.2005.01.005 }}</ref>

CP 55,940 induced cell death in NG 108-15 Mouse neuroblastoma x Rat glioma hybrid brain cancer (genetically engineered mouse x rat brain cancer) cells.<ref>{{ cite journal |author1=Tomiyama, K. |author2=Funada, M. | title = Cytotoxicity of synthetic cannabinoids found in 'Spice' products: The role of cannabinoid receptors and the caspase cascade in the NG 108-15 cell line | journal = Toxicology Letters | year = 2011 | volume = 207 | issue = 1 | pages = 12–17 | pmid = 21907772 | doi = 10.1016/j.toxlet.2011.08.021 }}</ref><ref>{{ cite web | url = http://www.hpacultures.org.uk/products/celllines/generalcell/detail.jsp?refId=88112302&collection=ecacc_gc | title = General Cell Collection: NG108-15 | publisher = Public Health England Culture Collections }}</ref>

==See also==
* [[CP 47,497]]

==References==
{{reflist}}

{{Cannabinoids}}
{{Hallucinogens}}
{{Cannabinoidergics}}

[[Category:Alcohols]]
[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Pfizer]]
[[Category:Phenols]]
[[Category:CB1 receptor agonists]]
[[Category:CB2 receptor agonists]]


{{nervous-system-drug-stub}}